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Background: Mild-to-moderate iodine deficiency is still present in many countries, particularly in pregnant
women. Observational studies suggest that mild-to-moderate iodine deficiency during pregnancy may be as-
sociated with impaired thyroid function and child neurodevelopment. Randomized-controlled food trials to
increase iodine status are scarce. We assessed the impact of an increased intake of cod during pregnancy on
maternal iodine status and infant neurodevelopment.
Methods: In this randomized-controlled trial, pregnant women in Bergen, Norway, recruited through Haukeland
University Hospital, were randomly assigned (1:1) to an intervention of 200 g of cod twice a week for 16 weeks
(gestational week 20–36) or to continue with their standard diet (control group). Randomization was done by
lottery. Primary outcome was urinary iodine concentration (UIC) (spot samples from six consecutive days)
measured postintervention. Secondary outcome was infant neurodevelopment assessed by the cognitive, lan-
guage, and motor scales of the Bayley Scales of Infant and Toddler Developmental third edition (Bayley-III)
at 11 months of age. In addition, maternal thyroid function was measured (thyrotropin [TSH], free triiodo-
thyronine [fT3], free thyroxine [fT4]) at baseline and postintervention.
Results: Between January 2016 until February 2017, 137 women were recruited. Postintervention UIC was
higher in the intervention group (n = 61) [median (interquartile range, IQR) 98 (64–145) lg/L], compared with
control (n = 61) [median (IQR) 73 (52–120) lg/L] ( p = 0.028), also after adjusting for baseline UIC ( p = 0.048).
Infants of mothers in the intervention group had a lower cognitive composite score on the Bayley-III compared
with the control group ( p = 0.045). There were no group differences in the Bayley III language- or motor
composite scores. Maternal thyroid hormones (TSH, fT3, fT4) did not differ between the groups postintervention.
Conclusions: Increased cod intake during pregnancy improved the iodine status in women with mild-to-moderate
iodine deficiency, however, did not affect thyroid function. The negative effect on cognition should be followed
up to assess whether this is a stable effect over time. More studies are warranted to enable good health advice on
iodine nutrition in pregnancy. ClinicalTrials.gov NCT02610959. Registered November 20, 2015.
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Introduction
Although substantial progress has been made to-ward improving iodine status worldwide, iodine defi-
ciency remains a significant health problem in low-,
middle-, and high-income countries (1). Severe iodine de-
ficiency is almost completely eradicated, mainly through
salt iodization programs (2). However, mild-to-moderate
iodine deficiency is still present in many countries, par-
ticularly in women of childbearing age, where Europe is the
continent with the highest prevalence of iodine deficiency
worldwide (3).
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Iodine is an essential micronutrient because of its incor-
poration in the thyroid hormones triiodothyronine (T3) and
thyroxine (T4). Pregnancy is a period of increased iodine
requirements to maintain euthyroidism due to transfer of
iodine and thyroid hormones to the fetus (4). Consequently,
pregnant women are vulnerable to iodine deficiency.
The World Health Organization (WHO) recommends an
iodine intake of 150 lg/day for nonpregnant women and
250 lg/day for pregnant women and the Nordic Nutrition
Recommendations recommend 150 lg/day for nonpregnant
women, 175 lg/day for pregnant women, and 200 lg/day for
lactating women (2,5). WHO recommends using the median
urinary iodine concentration (UIC) to assess iodine status in
population groups. A median UIC of 150–250 lg/L indicates
optimal iodine nutrition in pregnant women, while a UIC
<150 is considered insufficient (2). The Nordic Nutrition
Recommendations of 175 lg/day corresponds to a UIC of
*100 lg/L. Observational studies have found adverse health
effects when UIC falls below 100 lg/L, indicating that this may
be proposed as a cutoff for sufficiency during pregnancy (6,7).
Norway is currently a country of documented mild-to-
moderate iodine deficiency in pregnant women with median
UIC ranging from 75 to 92 lg/L (8–11). This may be caused by
the decrease in intake of milk and lean fish during the last de-
cade (12). Norway has no iodized salt, and milk, dairy products,
and seafood are the main dietary iodine sources of the total
iodine intake (8,13). After the completion of this trial, Nor-
wegian authorities have recommended iodine supplementation
of 150lg/day to pregnant women who have a lower daily in-
take than 6 dL of cow’s milk/yogurt (but eat white saltwater fish
regularly), or eat little/no white saltwater fish and at the same
time have a lower daily intake than 8 dL cow’s milk/yogurt.
Severe iodine deficiency is a well-known risk factor for
cognitive deficits in children (14,15). The effects of mild-to-
moderate iodine deficiency on cognitive development are
less certain. Few intervention studies on maternal iodine
supplementation on child development exist and randomized
control trials (RCTs) have been urgently called for (16,17).
To the best of our knowledge, this is the first intervention
trial in pregnant women with iodine-rich food (cod) to study
its effects on maternal iodine status and infant neurodeve-
lopment. The primary aim of this RCT was to investigate if
an increased intake of cod during pregnancy has an effect on
maternal iodine status, and secondarily if it has an effect
on infant neurodevelopment at 11 months of age.
Materials and Methods
Study design and participants
This study was a two-arm RCT with a primary aim of
studying the effect of increased cod intake during pregnancy
on maternal iodine status, and a secondary aim of deter-
mining infant neurodevelopment when the children were 11
months old. Participants were recruited through the Women’s
Clinic at Haukeland University Hospital, Health region
West, Norway. Approximately 5000 women give birth at the
Women’s Clinic annually. Once a pregnant woman was en-
rolled, the study investigators made every reasonable effort
to follow the participant closely for the entire trial period to
ensure the best possible retention. Before all the visits, the
participants were reminded about the upcoming appointment.
From January 2016 until February 2017, information re-
garding the intervention trial was included in the invitation
from the Women’s Clinic at the time of routine ultrasound in
gestational week 18. To increase the enrollment rate, infor-
mation regarding the trial and invitation to participate were
also broadcasted online (Facebook, Instagram, and in an online
magazine for pregnant women in Norway). Pregnant women
who were interested in the study contacted the researchers at
the Institute of Marine Research (IMR), Bergen, Norway.
Inclusion criteria were primiparous singleton pregnancy,
gestational week £19, and Norwegian speaking and/or un-
derstand Norwegian writing. Exclusion criteria were
allergies to fish and chronic diseases known to affect iodine
status (Graves’ disease, thyroiditis, thyroid nodules, known
hypothyroidism or hyperthyroidism). Participants gave writ-
ten informed consent after receiving written and oral infor-
mation about the study. No specific information about iodine
was given as the overall aim of the study was to study the
relationship between Mommy’s Food (nutrient intake in
pregnancy and the infants’ first year) and infant development.
The women could withdraw from the study at any time
without giving any reason. The trial complies with the Decla-
ration of Helsinki and was approved by the Regional Com-
mittee for Medical and Health Research Ethics West (2015/
879). The study protocol has been published elsewhere (18).
Randomization and masking
Baseline data were collected at the first visit, and during
gestational week 18–19. At the second visit in gestational
week 19, the participants were randomized individually by
lottery in blocks of 10 to ensure approximately equal allo-
cation to both groups. Owing to the nature of the intervention,
blinding of the participating mothers was not possible. Study
investigators (L.K.M. and I.N.) generated the random allo-
cation sequence, enrolled participants, and assigned partici-
pants to groups. Laboratory personnel were blinded when
analyzing data with no access to the code. Study investigators
(M.W.M. and S.N.) were blinded when analyzing the pri-
mary and secondary outcomes as the code was masked with
dummy variables by a third study investigator (L.K.M.).
Intervention
After randomization, participants in the intervention group
received frozen cod fillets (Lerøy A/S, Bergen, Norway) and
were instructed to consume two intervention meals of 200 g
weekly (a total of 400 g cod per week) for 16 weeks (a total of
32 meals) from gestational week 20 to 36. The participants
also received cod for their partner, if any, with the intention to
increase compliance. The participants prepared the meals
themselves and could choose their own recipes but were
also provided with recipes that could be used ad libitum. For
compliance purposes, participants were instructed to weigh
(Kitchen Scale, Article No. 34–1207-16, ClasOhlson.com)
the cod fillet before preparing the meals, and weigh the fillet
leftovers (if any), after the meals were eaten. The participants
recorded these data in a weight registration form, in addition
to recipes used, and date of consumption.
To calculate total gram cod eaten each meal, gram cod
after preparation of the meal was subtracted from gram cod
before preparing the meal. Total gram cod for each meal
during the intervention period was then summarized to get a
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value of total gram cod eaten during the intervention period.
Total intake of cod was divided by 16 weeks to get a mean
weekly intake of cod. Total intake of cod was divided by a
maximum intake of cod during the intervention period
(200 g · 32 meals = 6400 g) and multiplied with 100 to get a
compliance score. Example of a total intake of 6400 g during
the intervention or a mean intake of 400 g cod per week
provided a compliance score of 100. The participants in the
control group were instructed to continue to follow their
habitual diet, without any restrictions.
Outcomes
The primary outcome was UIC measured at postinter-
vention. At the first visit in gestational week 18, participants
received six marked collection tubes for the collection of
urine samples on six consecutive days from gestational week
18–19, with instructions on how to collect the spot urine sam-
ples. Before the visit in gestational week 36, postintervention,
participants received by mail six marked collection tubes for
the collection of urine samples on six consecutive days from
gestational week 35–36. The participants kept the urine
samples in their home freezer until the visits in gestational
week 19 and 36, respectively. Equal amounts of urine from
the six spot urine samples (collected on six consecutive days
between 4 pm and midnight) were homogenized into one
pooled sample of 1 mL urine and were stored at -20C in
cryotubes (CryoTube Vials Nunc; Thermo Fischer Scien-
tific, Roskilde, Denmark) pending analysis by inductively
coupled plasma mass spectrometry (ICP-MS).
Before the analysis, the urine samples were defrosted in a
refrigerator, diluted with 1% tetramethylammonium hy-
droxide filtrated using a sterile membrane filter (0.45 lm pore
size), and transferred to tubes appropriate for the analysis by
the Agilent 7500 for ICP-MS at IMR. Samples were analyzed
against a urine calibration curve (standard addition curve) to
measure the unknown iodine concentration (127I) in the col-
lected urine samples. Accuracy was verified with certified
reference material; Seronorm Trace Elements Urine (Ny-
comed Pharma, Norway), iodine content: 84 lg/L (range 72–
96 lg/L) and 304 lg/L (range 260–348 lg/L). The mea-
surement uncertainty of the method has been assessed based
on internal reproducibility, analysis of standard reference
material, and is set at 20% in the entire range (2–297 lg/L).
The limit of detection was 2 lg/L.
For thyroid function and docosahexaenoic acid (DHA)
analysis, blood samples were drawn in gestational week 18
and 36. Blood samples for serum preparation were collected in
BD Vacutainer SST vials II Advanced and set to coagulate
for a minimum of 30 minutes before centrifuging (1000–3000
g, room temperature, 10 minutes) within 60 minutes after
extraction. Blood samples for red blood cell preparation were
collected in BD Vacutainer K2E 5.4 mg vials and centrifuged
(1000–1300 g, 20C, 10 minutes) within 30 minutes.
Postseparation, serum samples were stored at -80C pend-
ing analysis at Fürst Medical Laboratories (Norway), and red
blood cell samples were stored at -80C pending analysis at
IMR. The serum samples were stored for a maximum of three
months before analysis. Thyrotropin (TSH), free thyroxine
(fT4), and free triiodothyronine (fT3) were analyzed in serum
using magnetic separation and detection by chemilumines-
cence, labeled with acridinium ester, on an Advia Centaur
XPT Immunoassay system (Siemens Healthcare Diagnostics,
Inc., Tarrytown, NY). For all blood constitutes, the coefficient of
variation was <6%. DHA was analyzed in red blood cells by a
standardized procedures at IMR (19), using ultrafast gas chro-
matography (Thermo Electron Corporation, Franklin, MA).
The secondary outcome was neurodevelopment assessed
by the cognitive, language, and motor scales of the Bayley
Scales of Infant and Toddler Developmental third edition
(Bayley-III) when the infants were 11 months of age. The
Bayley-III is a comprehensive assessment tool of neurode-
velopment administered directly with the child (20). The
tool takes *45 to 60 minutes to administer and includes
three main subscales: the cognitive, language (receptive and
expressive), and motor (fine and gross motor) scales. The
Bayley-III represents the gold standard of developmental
assessment in this age group and is widely used as an out-
come measure in clinical trials. The official Norwegian ver-
sion of the Bayley-III translated and adapted for a Norwegian
setting was used, with American norms from a representative
American sample.
The Bayley-III provides 5 scaled scores [mean 10, range 1–
19, standard deviation (SD) 3] and 3 composite scores (mean
100, range 40–160, SD 15) (21). Two trained testers (L.K.M.
and I.N.), supervised by a neuropsychologist (M.H.) and a
clinical child psychologist (I.K.), administered the Bayley-III
in the current trial. Standardization exercises were conducted
before the start of the study assessment until a satisfactory
level of agreement was reached. During the trial, 20% of the
tests were double scored with an interclass correlation ranging
from 0.88 to 0.99, indicating high inter-rater agreement.
Background variables
Demographic information, including education, income,
prepregnancy and current weight, height, and nicotine use in
pregnancy, was collected through an electronic questionnaire
at baseline in gestational week 18–19. Gestational length and
birthweight were obtained from birth records by the mother’s
recall. Preterm delivery was defined as birth <gestational
week 37 and low birthweight as <2500 g.
Iodine intake
Iodine intake was estimated from a structured six-day
iodine-specific food diary designed and validated for this
study (22). The food diary was filled out on six consecutive
days at baseline and postintervention (between gestational
week 18–19 and gestational week 35–36, respectively) at the
exact same days as the spot urinary samples. The food diary
included food items of iodine-rich foods (fish and seafood,
milk and dairy products, and eggs) in addition to supplements
used. The food diary was developed specifically for this study
and has been validated and described in detail by Næss et al.
(22). The article includes information of iodine content of the
specific food items used, including cod, for calculation of
iodine intake. For data on the use of iodine supplements since
becoming pregnant, we used data from an iodine-specific
food frequency questionnaire, which is also validated and
described in detailed by Næss et al. (22). To retrieve the
iodine content of the cod given in the intervention, 30 indi-
vidual cod samples from the batch used in the intervention
were analyzed at the IMR using ICP-MS, the method has
previously been described in detail elsewhere (23).
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Statistical analysis
The power calculation for the sample size in the current
study was based on data on a median (IQR) UIC of *80 (80)
lg/L in pregnant women from the ‘‘Little in Norway’’ cohort
(9,24). The sample size was calculated to detect a 30% dif-
ference in UIC between the intervention and control groups.
The intended sample size was thus 60 individuals per group
(total of 120) (0.05 one-tailed alpha, power 0.952). To ac-
count for attrition, 24 (20%) subjects were added reaching a
final intended sample size of 144 (18,25).
The continuous variables are summarized as mean – SD or
median [interquartile range (IQR)], and the categorical vari-
ables are described in frequency and percent. Analyses were
performed on an intention-to-treat basis, and missing cases
were omitted from the data set (listwise deletion) (26). Nor-
mality was assessed by testing the distribution of continuous
variables against a normal distribution using the Shapiro–Wilk
W test. For the primary outcome, we present the median (IQR)
UIC lg/L at baseline and postintervention. UIC data were
transformed using log10 to correct for positive skewness.
In the main primary analysis, the Student’s t-test was used
to compare potential within- and between-group differences,
and a one-way analysis of covariance (ANCOVA) was used
to compare the differences in postintervention UIC lg/L
between the groups, with baseline UIC lg/L included as a
covariate. We included baseline UIC in the model as it is
believed that the postintervention UIC to some degree de-
pends on the baseline UIC lg/L. We also assessed whether
UIC had remained stable, increased, or decreased between
the baseline and postintervention. An increase and decrease
were defined as a change larger than –10% from baseline to
postintervention, which were chosen according to the mea-
surement uncertainty of 20%.
The Student’s t-test was used to compare potential within-
and between-group differences in thyroid hormone levels
(TSH, fT3, and fT4), and a one-way ANCOVA was used to
compare the differences in postintervention concentrations
between the groups with the baseline concentrations included
as a covariate.
For the secondary outcome, we present the mean (SD) of
the Bayley-III cognitive composite score, the language scaled
scores (receptive and expressive) and composite scores, and
the motor scaled scores (fine and gross) and composite
scores. We used a Student’s t-test to compare the means
between the groups. For all analyses, a two-sided p-value of
< 0.05 was considered statistically significant. Statistical
analyses were performed using Statistical Package for the
Social Sciences (SPSS Statistics Version 25).
Results
A total of 165 pregnant women showed interest in par-
ticipating in the study by contacting the study secretariat.
From January 2016 until February 2017, a total of 137
pregnant women were enrolled in the study and signed the
informed consent. Between the enrollment and randomiza-
tion, 4 participants withdrew from the study, and in total, 133
pregnant women were randomized to the intervention group
(n = 68) or the control group (n = 65). Between randomization
and post-testing, nine participants dropped out of the study
[six (8.8%) in the intervention group and three (4.6%) in the
control group]. In addition, two participants were lost to
follow-up due to preterm delivery. Hence, for the primary
outcome (UIC), 122 participants [n = 61 (89.7%) in the in-
tervention group and n = 61 (93.8%) in the control group]
were included in analysis.
For the secondary outcome (Bayley-III), 112 participants
[n = 57 (83.8%) in the intervention group and n = 55 (84.6%)
in the control group] were included in the analyses. There
were no differences in any baseline characteristics between
participants who withdrew from the study and those who
completed the study at 11 months (Supplementary Table S1).
An overview of the recruitment and flow of participants
through the trial is outlined in Figure 1. Baseline character-
istics for the randomized pregnant women were similar in the
two groups (Table 1).
Mean compliance score was 77, ranging from 35 to 102.
More than 70% of the participants had a compliance score of
more than 70. Approximately 50% of the participants had a
compliance score of more than 80. Less than 10% had a
compliance score of <50. The mean (SD), median (IQR), and
5 percentile intakes of the received cod in the intervention
group were 306 (62), 318 (275–356), and 175 g per week,
respectively. The mean (IQR, min, max) analyzed iodine
content of the cod given in the intervention based on analy-
sis of 30 individual cod samples was 81 (46–71, 31, 630)
lg/100 g. There were no reported adverse events during or
after the intervention.
In total, six infants were delivered preterm (<gestational
week 37) (n = 3 in the control group, n = 3 in the intervention
group), and three infants were born with low birthweight
(<2500 g) (n = 2 in the control group, n = 1 in the intervention
group). There was no difference between gestational length
[control group: mean (SD): 40.2 (2.6) weeks, intervention
group: mean (SD): 40.3 (1.8) weeks] and birthweight [control
group: mean (SD): 3442 (589) g, intervention group: mean
(SD): 3541 (478) g] between the groups.
For the main analysis, the UIC was significantly higher in
the intervention group postintervention [median (IQR) 98
(64–145) lg/L], compared with the control group [median
(IQR) 73 (52–120) lg/L] ( p = 0.028). The difference between
the groups was still significant after adjusting for baseline UIC
lg/L [log mean (SD) control group: 1.89 (0.027), log mean
(SD) intervention group: 1.96 (0.027), mean difference be-
tween log means: 0.076 [confidence interval, CI 0.001–0.150],
p = 0.048] (Table 2). The estimated iodine intake post-
intervention was significantly higher ( p = 0.001) in the inter-
vention group [median (IQR, min, max) 218 (156–323, 45,
481) lg/day, n = 61] compared with the control group [median
(IQR, min, max) 146 (87–264, 32, 423) lg/day, n = 61].
For the secondary outcome, the intervention group had a
significant lower cognitive composite score on the Bayley-III
compared with the control group, when the infants were 11
months of age [log mean (SD) control group: 1.99 (0.049), log
mean (SD) intervention group: 1.97 (0.04), mean difference
between log means: 0.016 [CI 0.0004–0.0321], p = 0 $ 045].
There were no significant differences in the Bayley-III lan-
guage- or motor composite scores between the groups (Table 3).
Table 4 shows change in UIC from baseline to post-
intervention in the control and intervention groups. The
number of participants with an increase in UIC was 28% in
the control group and 36% in the intervention group, while
the number of participants with a decrease in UIC was 51%
and 36% in the control and intervention groups, respectively.
























































































































































































































































































































































































































































































































































































































































































































The thyroid hormones TSH, fT3, and fT4 did not differ be-
tween the groups postintervention (Table 5). There was no
difference in DHA status neither at baseline nor postinter-
vention between the groups (Supplementary Table S2).
Discussion
To our knowledge, this is the first RCT to investigate the
effect of nonfortified iodine-rich food consumption in preg-
nancy on maternal iodine status and infant neurodevelopment.
In concordance with other recent studies in Norwegian and
other European pregnant populations, the pregnant women in
this study were mildly-to-moderately iodine deficient at
baseline. After the intervention with two meals of cod for a
period of 16 weeks in pregnancy (gestational week 20–36),
median UIC was significantly higher in the intervention group
compared with the control group. However, the median UIC
values remained below the recommended UIC of 150 lg/L.
The children’s language and motor scores on the Bayley-III
were similar in both groups when assessed at 11 months of
age, while the cognitive score was better in the control group.
Our results suggest that it is possible to improve the iodine
status during pregnancy using a nutrition-sensitive food
system approach to meet the dietary requirements of a pop-
ulation (27). Several RCTs have previously been conducted
to improve the iodine status in pregnancy, using iodine-
containing supplements (28). In countries without iodized
salt, such as in Norway and the United Kingdom, it is im-
portant to include one or several key sources of iodine in
the habitual diet to achieve an adequate iodine intake. The
present study shows that cod has a potential as an important
dietary source of iodine in pregnancy when included in the
diet. However, median UIC after the intervention did not
meet the epidemiological criteria for adequate iodine nutri-
tion (median UIC between 150 and 250 lg/L) suggested by
the WHO (2). Although the suggested limit of *100 lg/L,




Age, years, mean (SD) 65 29.1 (3.5) 68 29.6 (4.0)
BMI, kg/m2 62 23.3 (4.3) 68 22.9 (3.9)
Education, years, % 63 68
‡12 7 11.1 11 16.2
13–16 15 23.8 18 26.5
>16 41 65.1 39 57.4
Household income (NOKa), % 63 68
Low (<200,000–549,000) 15 23.8 23 33.8
Medium (550,000–1,249,999) 40 63.5 36 52.9
High (1,250,000 to >2,000,000) 8 12.7 9 13.2
Nicotine use in pregnancy,b yes, % 62 68
£gestational week 8 7 11.3 5 7.4
>gestational week 8 0 0 0 0
Iodine intake, lg/day, median (IQR)c 65 133 (81–240) 68 152 (92–267)
Milk and dairy 65 67 (43–92) 68 62 (22–76)
Egg 65 7 (3–14) 68 7 (3–14)
Seafoodb 65 33 (94) 68 42 (94)
Supplements (users only) 21 175 (135–200) 25 150 (131–175)
Iodine supplement use since becoming pregnant, n (%)d 59 21 (32) 63 29 (43)
aOne hundred NOK =*11.6 USD/10.2 EUR.
bNo participants reported use of nicotine after gestational week 8.
cIntake estimated from six-day food dairy at baseline.
dReported from food frequency questionnaire.
BMI, body mass index; IQR, interquartile range; NOK, Norwegian Krone; SD, standard deviation.
Table 2. Urinary Iodine Concentration at Baseline and Postintervention
in the Mommy’s Food Trial Participants
UIC, lg/La Difference between groups postintervention
Baseline, median (IQR) Post, median (IQR) Crude, pb Adjusted, pc
Control (n = 61) 85 (55–130) 73 (52–120) 0.028 0.048d
Intervention (n = 61) 88 (64–130) 98 (64–145)
aAnalyzed in a pooled sample of six spot samples collected on six consecutive days at each time point.
bIndependent sampled t-test for comparison of log-transformed values.
cOne-way ANCOVA for comparison of differences between control and intervention groups adjusted for baseline UIC (lg/L). A two-
sided p-value of < 0.05 was considered statistically significant.
dg2 = 0.033.
ANCOVA, analysis of covariance; UIC, urinary iodine concentration.
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based on the Nordic Nutrition Recommendations, was almost
met with a median of 98 lg/L in the intervention group (5).
The intervention group had a significantly lower score on
the cognitive composite score than the control group, while
the language and motor scores were similar between the
groups. Since this is the first RCT aiming at increasing iodine
status in pregnancy through a food-based approach, and sub-
sequently assessing child development, comparable studies
are lacking. In regions of severe iodine deficiency, iodine
supplementation in pregnancy has been shown to reduce the
incidence of cretinism and improve motor development in
children (16). However, the effects of iodine supplementation
during pregnancy in mildly-to-moderately iodine-deficient
populations are still unclear (16). A Cochrane review from
2017, including 11 trials, concluded that there was insuffi-
cient evidence for either the benefit or harm of iodine sup-
plementation during pregnancy on child neurodevelopment
due to small participant numbers and low quality of trials
(28). Only two of the RCTs included developmental out-
comes in children, and in those, there were no difference in
the developmental outcomes between the groups (29,30).
The first randomized, double-blinded, placebo-controlled
trial in mildly-to-moderately iodine-deficient pregnant wo-
men was conducted from 2008 to 2011 in India and Thailand.
They found no effect of 200 lg iodine per day from early
pregnancy (<gestational week 14) until delivery on child
cognition at 5–6 years of age (31). It is important to note that
although the median UIC of the two cohorts was indicative of
mild deficiency at baseline, one of the cohorts was actually
iodine sufficient, which potentially could have confounded
the results. However, an analysis of secondary outcomes at
age one year showed higher scores for expressive language
measured by the Bayley III in the placebo group than in the
iodine intervention group (31). Likewise, we found a higher
Bayley III score on cognition in the control group than in the
intervention group. However, the effect size of the difference
between the groups was small, and the mean cognitive level
was close to average for both the control and intervention
groups. Still, the mean difference in Bayley-III cognitive score
of four points could reflect important differences in learning
and development. Follow-up studies investigating stability and
trajectories are needed to conclude on the impact of these
differences. Although more uncertain on an individual level,
small effects may be meaningful on a public health level.
Results from a few RCTs and observational studies suggest
that introducing an iodine supplement after the onset of
pregnancy in women with mild-to-moderate iodine defi-
ciency can have adverse effects on thyroid hormones and
infant development (28,32–35). Furthermore, a recent sys-
tematic review and meta-analysis of the effects of iodine
supplementation on thyroid function and child neurodeve-
lopment in mildly-to-moderately iodine-deficient pregnant
women concluded that there is insufficient good-quality
evidence to support current recommendations for iodine
supplementation in pregnancy in areas of mild-to-moderate
deficiency (36). Despite these ambiguous results, routine
iodine supplementation in pregnancy is recommended by
health authorities across the world.
Table 3. Infant Neurodevelopment Assessed












99 (10) 95 (9) 0.045c
Language composite
scores
95 (8) 96 (8) 0.67
Receptive language-
scaled score
8 (2) 8 (2) 0.20
Expressive language-
scaled score
11 (1) 11 (1) 0.36
Motor composite scores 94 (8) 92 (7) 0.24
Gross motor-scaled
score
9 (2) 9 (2) 0.85
Fine motor-scaled
score
9 (1) 9 (2) 0.13
aNeurodevelopment was assessed by the cognitive, language, and
motor scales of the Bayley Scales of Infant and Toddler Develop-
mental third edition.
bIndependent t-test of differences for comparison of log-
transformed values between groups. Language composite scores
owing to normality. A two-sided p-value of < 0.05 was considered
statistically significant.
cCohen’s d = 0.42.
Table 4. Change in Urinary Iodine Concentration from Baseline


















<50 4 (7) 5 (8) 3 (5) 7 (12) 0 0 0.034
50–100 9 (15) 9 (15) 4 (7) 15 (25) 7 (12) 9 (15) 0.243
>100 4 (7) 17 (28) 6 (10) 3 (5) 15 (25) 5 (8) 0.847
All 17 (28) 31 (51) 13 (21) 25 (41) 22 (36) 14 (23) 0.081
Increase and decrease were defined as a change larger than –10% from baseline to postintervention.
aPercent within control group.
bPercent within intervention group.
cDifferences tested between increase and decrease in the control and intervention groups using Pearson’s chi-square test or Fisher’s exact
test. A two-sided p-value of < 0.05 was considered statistically significant.
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The possible underlying mechanisms of all iodine defi-
ciency disorders (IDDs), including impaired child develop-
ment, are inadequate thyroid hormone production and their
disturbed action in target tissues (37). Correcting iodine de-
ficiency has proven beneficial to prevent IDDs worldwide
(38,39). However, iodine supplementation or fortification has
also been associated with increased incidence of thyroid
dysfunction (40). Even though we managed to increase the
iodine status in the intervention group, it might have been too
late as the first trimester of pregnancy is crucial as the fetal
brain development is dependent on maternal thyroid hormone
transfer (41). Moreover, not all participants in the intervention
group had an increase in UIC from baseline to postinterven-
tion, which may have interfered with the secondary outcome.
Still, for those participants who had a UIC <50 lg/L at base-
line, the intervention group differed from the control group in
that all the participants had an increase in UIC from baseline to
postintervention. Nevertheless, we cannot exclude the possi-
bility that the alterations in iodine intake during pregnancy
could have a negative effect on maternal thyroid function and
hence child cognition. Noteworthy, a temporal stunning of
thyroid function has been discussed to be as a consequence of
changes in iodine intake in mildly-to-moderately iodine-
deficient populations, and not solely as a consequence of ex-
cessive iodine intake (42,43). In the current study, the wom-
en’s iodine intake could not be characterized as excessive.
The differences in UIC concentration and estimated iodine
intake between groups after the intervention were not re-
flected in the thyroid hormones that were similar in the
groups postintervention. However, individuals have a genetic
set point for thyroid hormone concentrations and, despite a
wide interindividual variation, there is a low index of indi-
viduality (44). Nonetheless, there is a possibility that a small
change in the habitual maternal iodine intake during preg-
nancy, rather than before pregnancy, might have changed
fetal thyroid hormone status during this vulnerable period of
neurodevelopment. Thus, our finding urges further attention.
A key limitation in this study could be the onset of the
intervention as timing of exposure to maternal iodine insuf-
ficiency is a modulator for its effect on outcomes (45). In the
attempt of a nonbiased source population, the women were
recruited before their first meeting with the public health care
system at gestational week 18. Thus, baseline testing, ran-
domization, and onset of the dietary intervention did not
commence before gestational week 18 and 19. Blinding is a
challenge in RCTs with food. We have previously conducted
RCTs with fish in kindergarten children and youths preparing
identical meals to intervention and control groups, the only
difference being the protein source (46,47). However, due to
both texture and taste, blinding was not possible. RCTs with
single dietary components are inconclusive in confirming
health outcomes from observational studies. This could be
due to the complexity of food containing several bioactive
components. Thus, RCTs with food are still valuable despite
the challenge of blinding (48).
A limitation or rather a consequence of a dietary inter-
vention introducing a food (e.g., lean fish) twice a week is
replacement of another habitual food (e.g., fatty fish). While
lean fish is a good source of iodine, fatty fish is an excellent
source of DHA, a nutrient also playing a critical role in brain
development (49,50). Details regarding the seafood intake of
the participants in this study have recently been described in
detail elsewhere (51). While the control group had a stable
intake of both lean and fatty fish, the intervention group in-
creased its intake of lean fish and decreased the intake of fatty
fish from baseline to postintervention. The intervention group
had a higher DHA status compared with the control group
postintervention, although the difference was not significant.
Still, the higher DHA status in the intervention group is not
likely to confound the effects of interest or have a large im-
pact on the cognitive outcomes.
As lean fish also is a source of mercury, we also measured
mercury status at baseline and postintervention (51). How-
ever, the concentrations of mercury were low and only a
small difference between the groups was observed; so, we do
not believe this has affected the results. Furthermore, the
iodine content of the cod given in the intervention was low
compared with the reported values in the Norwegian food
composition table. Laboratory analysis also showed large
variation in the individual cod fillets. Thus, the dose given in
each meal and to each participant in the intervention group is
believed to have varied, introducing a dose bias.
Table 5. Thyrotropin, Free Triiodothyronine, and Free Thyroxine in Intervention and Control Groups
at Baseline (gw 18) and Postintervention (gw 36) in the Mommy’s Food Trial Participants
Thyroid hormones Difference between groups postintervention
Baseline, mean (SD) Post, mean (SD) Crude, pa Adjusted, pb
TSH, mIU/L
Control (n = 58) 1.6 (0.7) 1.8 (0.8) 0.94 0.89
Intervention (n = 61) 1.6 (0.8) 1.8 (0.8)
fT3, pmol/L
Control (n = 58) 4.3 (0.4) 3.8 (0.4) 0.18 0.10
Intervention (n = 61) 4.2 (0.5) 3.9 (0.4)
fT4, pmol/L
Control (n = 58) 13.8 (1.5) 13.5 (1.9) 0.87 0.60
Intervention (n = 61) 14.0 (1.7) 13.4 (1.4)
aIndependent t-test of differences between groups postintervention.
bOne-way ANCOVA for comparison of differences between control and intervention groups adjusted for baseline levels. A two-sided
p-value of < 0.05 was considered statistically significant.
fT3, free triiodothyronine; fT4, free thyroxine; gw, gestational week; TSH, thyrotropin.
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We did not correct for multiple testing for the secondary
outcome, and thus, the risk of detecting false-positive results
(type 1 error) might have increased. However, correction for
multiple testing has been debated as it also decreases the
statistical power and increases the risk of not detecting real
differences (type 2 error) (52).
Strengths of this study are the high compliance and the
analysis of a pooled sample of six spot urine samples at
baseline and postintervention in both groups, including both
weekdays and weekend. Although 10 samples are suggested
for assessing individual iodine status, 6 samples could be
enough to categorize individual status based on UIC as there
was a strong agreement with the food diary, recorded on the
same six consecutive days (22,53).
In conclusion, an increased intake of iodine through con-
sumption of cod in mildly-to-moderately iodine-deficient
pregnant women resulted in an increased iodine status mea-
sured as UIC. The intervention had no measurable effect on
maternal thyroid function, and the infants of the mothers in
the intervention group had a lower cognitive score compared
with the control group. A follow-up of these children over
time will indicate if these differences persist. While the
overall literature is ambiguous, there is a need to investigate
further both positive and possible adverse effects of increas-
ing iodine intake in pregnancy, rather than ideally before
conception, to assure the safety of the present guidelines.
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